Werewolf Therapeutics posted no revenue for Q2 2025 and recorded a net loss of $18.0M. The company continued advancing clinical trials for WTX-124 and WTX-330 and announced a new preclinical candidate, WTX-1011. Operating expenses declined YoY, and cash reserves were reported at $77.6M.

Werewolf Therapeutics experienced a net loss of $18.089 million in the first quarter of 2025, compared to a net loss of $16.193 million in the same period last year. The company reported no collaboration revenue for the current quarter, a decrease from $742 thousand in Q1 2024. Research and development expenses increased slightly to $13.120 million, while general and administrative expenses saw a minor decrease. The company's cash and cash equivalents stood at $92.042 million as of March 31, 2025.

Werewolf Therapeutics reported a net loss of $20.4 million for Q4 2024, compared to a net loss of $12.0 million in Q4 2023. Collaboration revenue was $0 for Q4 2024, down from $1.5 million in Q4 2023. Research and development expenses increased significantly to $15.7 million from $9.6 million in the prior year.